Capula Management’s Moderna MRNA Stock Holding History

Capula Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-50,000	Closed	-$2.54M	–	992
2026 Q1	$2.54M	Buy	+50,000	New	+$2.33M	0.02%	214
2025 Q3	–	Sell	-2,400	Closed	-$66.2K	–	863
2025 Q2	$66.2K	Buy	+2,400	New	+$63.2K	﹤0.01%	564
2024 Q3	–	Sell	-1,400	Closed	-$166K	–	585
2024 Q2	$166K	Sell	1,400 -2,100	-60%	-$266K	﹤0.01%	398
2024 Q1	$373K	Buy	+3,500	New	+$353K	0.01%	299
2023 Q3	–	Sell	-21,900	Closed	-$2.66M	–	611
2023 Q2	$2.66M	Sell	21,900 -33,800	-61%	-$4.51M	0.06%	127
2023 Q1	$8.55M	Buy	+55,700	New	+$9.19M	0.1%	171
2022 Q4	–	Sell	-14,700	Closed	-$1.74M	–	844
2022 Q3	$1.74M	Buy	+14,700	New	+$2.23M	0.02%	375
2021 Q4	–	Sell	-3,600	Closed	-$1.39M	–	574
2021 Q3	$1.39M	Hold	3,600	–	–	0.02%	464
2021 Q2	$846K	Buy	+3,600	New	+$643K	0.01%	386

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Capula Management's MRNA Position: Q2 2026 in Review

Capula Management sold out of Moderna (MRNA) in Q2 2026, closing a stake of 14,500 shares — an estimated $737K sold.

Capula Management first reported a position in MRNA in Q2 2021 and held it in 10 quarters. The position peaked at $962K in Q3 2022. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Capula Management reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
Capula Management sold 14,500 Moderna shares in Q2 2026, an estimated $737K.
Capula Management first reported a position in Moderna in Q2 2021 and held it in 10 quarters.
Capula Management's Moderna position peaked at $962K in Q3 2022.
784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Capula Management's 13F filing for Q2 2026, filed 14 Aug 2026.